Relievant Medsystems Introduces Intracept Simulator System Powered by Medability for Improved and Expanded Physician Training Opportunities

by Ben Anderson | Sep 21, 2023 | news

Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic pain CHICAGO – IPSIS Annual Meeting – September 21, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back...

Relievant Medsystems Announces Pooled Analysis Demonstrating the Intracept Procedure Significantly Reduces Low Back Pain-related Healthcare Utilization

by Ben Anderson | Sep 12, 2023 | news

Findings show marked reductions in need for opioids and therapeutic lumbosacral spine injections five years post-procedure MINNEAPOLIS – September 12, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low...

Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure

by Ben Anderson | Jul 20, 2023 | news

Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low Back Pain Minneapolis – July 20, 2023 – Relievant Medsystems, a company dedicated to transforming the...

Relievant Medsystems Announces More Than 10,000 Patients Treated with the Intracept® Procedure for Vertebrogenic Low Back Pain

by Ben Anderson | May 9, 2023 | news

MINNEAPOLIS – May 9, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that more than 10,000 patients have been treated with the Intracept® Procedure. This is the latest in a...

Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain

by Ben Anderson | Apr 19, 2023 | news

MINNEAPOLIS – April 19, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that it has completed the close of its $50 million Series G financing....